Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL
Epcoritamab monotherapy is well tolerated and efficacious in patients with r/r CLL
Teclistamab-lenalidomide and teclistamab alone can be safely administered as maintenance therapy following ASCT in NDMM
Mosunetuzumab SC plus polatuzumab vedotin demonstrates improved outcomes versus rituximab plus polatuzumab vedotin in RR LBCL
Acalabrutinib plus venetoclax with or without obinutuzumab versus chemoimmunotherapy for first-line treatment of CLL
Primary IVIG supplementation reduces the risk of high-grade infections in patients receiving teclistamab therapy for MM
Glofitamab with rituximab, ifosfamide, carboplatin and etoposide shows favourable efficacy in RR diffuse large B-cell lymphoma
Analysis of dexamethasone-enhanced pre-medication in motixafortide-induced haematopoietic stem cell mobilisation for MM
Pembrolizumab after chemo demonstrates promising activity in low-risk cHL
Analysis of pre-treatment biomarkers associated with toxicity and durable responses in idecabtagene vicleucel therapy for RRMM
Comparative safety and efficacy of ciltacabtagene autoleucel and idecabtagene vicleucel CAR T-cell therapies in RRMM
Bispecific antibody therapy for lymphoma patients failing CAR T-Cell therapy
Teclistamab-based induction regimens demonstrate manageable safety and efficacy in patients with transplant-eligible NDMM